ClinicalTrials.gg

Program

Insulin Glargine

Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.

Furthest: phase 4, since Sep 9, 2005184 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi1241 open or runningphase 4since Sep 9, 2005Sep 30, 2002none ahead
Novo Nordisk280 open or runningphase 4since Sep 12, 2005Oct 29, 2004none ahead
Eli Lilly250 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Diabetes Care Center20 open or runningno phasesince Apr 3, 2007Apr 3, 2007none ahead
Biodel10 open or runningphase 2since Oct 21, 2009Oct 21, 2009none ahead
Geropharm10 open or runningno phasesince Sep 23, 2019Sep 23, 2019none ahead
ikfe-cro-gmbh10 open or runningphase 4since Dec 5, 2011Dec 5, 2011none ahead
Profil Institut für Stoffwechselforschung10 open or runningphase 1since Sep 3, 2009Sep 3, 2009none ahead
Wockhardt10 open or runningphase 1since May 12, 2011May 12, 2011none ahead

Also a collaborator on its studies: ppd-development-lp, Alkermes and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Sep 14, 2012.

  1. Dec 5, 2018Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT03767543 · 265 enrolled · Canada
  2. Jan 7, 20192 phase 3 studies in Diabetes Mellitus, Type 2Sanofi · NCT03798080, NCT03798054
  3. Aug 29, 2019Phase 4 study in Diabetes Mellitus, Type 1Sanofi · NCT04075513 · 343 enrolled · United States, Brazil, Germany and more
  4. Sep 23, 2019Geropharm's first study: no phase study in Clamp StudyNew to GeropharmGeropharm · NCT04101383 · 42 enrolled · Russian Federation
  5. Nov 5, 2019Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04153981 · 304 enrolled · India
  6. Jul 10, 2020No phase study in Diabetes Mellitus, Type 1Eli Lilly · NCT04484779 · 67 enrolled · United States
  7. Apr 27, 2021Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04864977 · United States
  8. Jul 19, 2021Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT04980027 · 228 enrolled · India
  9. Oct 29, 2021Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT05114590 · 124 enrolled · United States
  10. Jun 7, 2022Phase 3 study in Diabetes Mellitus, Type 2Sanofi · NCT05413369 · 582 enrolled · China
  11. Jul 14, 2022Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT05462756 · 730 enrolled · United States, Argentina, Germany and more
  12. Sep 7, 2022Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT05552859 · 62 enrolled · United States, Czechia, Hungary and more
  13. Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2Novo Nordisk · NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
  14. Oct 31, 2024Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT06671587 · 678 planned · China

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The newest 60 of 184 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06671587Diabetes Mellitus, Type 2 · China4RecruitingSanofiSep 18, 2026678
NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more3CompletedNovo NordiskMay 8, 2025412
NCT05552859Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more4TerminatedSanofiJul 28, 202362
NCT05462756Diabetes Mellitus, Type 2 · United States, Argentina, Germany and more3CompletedEli LillyFeb 27, 2024730
NCT05413369Diabetes Mellitus, Type 2 · China3CompletedSanofiOct 20, 2023582
NCT05114590Diabetes Mellitus, Type 2 · United States4CompletedSanofiMar 28, 2023124
NCT04980027Diabetes Mellitus, Type 2 · India4CompletedSanofiDec 23, 2022228
NCT04864977Diabetes Mellitus, Type 2 · United States4WithdrawnEli LillyJun 6, 20220
NCT04484779Diabetes Mellitus, Type 1 · United States–CompletedEli LillyDec 22, 202067
NCT04153981Diabetes Mellitus, Type 2 · India4CompletedEli LillyJul 30, 2021304
NCT04101383Clamp Study · Russian Federation–CompletedGeropharmFeb 16, 201842
NCT04075513Diabetes Mellitus, Type 1 · United States, Brazil, Germany and more4CompletedSanofiSep 16, 2021343
NCT03798080Diabetes Mellitus, Type 2 · China3CompletedSanofiDec 1, 2020426
NCT03798054Diabetes Mellitus, Type 2 · China, Korea, Republic of, Malaysia and more3CompletedSanofiMar 1, 2021878
NCT03767543Diabetes Mellitus, Type 2 · Canada3CompletedSanofiOct 23, 2020265
NCT03760991Diabetes Mellitus, Type 2 · Argentina, Colombia, Egypt and more4CompletedSanofiSep 23, 2020372
NCT03555305Healthy · China1CompletedEli LillyNov 4, 201958
NCT03529123Diabetes Mellitus, Type 2 · India3CompletedSanofiNov 25, 2019247
NCT03434119Diabetes Mellitus, Type 2 · United States3TerminatedSanofiJan 7, 2019241
NCT03406000Diabetes Mellitus, Type 1 · Brazil4CompletedSanofiFeb 4, 2019170
NCT03359837Diabetes Mellitus, Type 2 · China4CompletedSanofiJun 29, 2020384
NCT03338023Diabetes Mellitus, Type 1 · China3CompletedEli LillyMar 5, 2020272
NCT03338010Diabetes Mellitus, Type 2 · China3CompletedEli LillyMar 18, 2020536
NCT03260868Diabetes Mellitus, Type 1 · United States, Canada4TerminatedSanofiNov 22, 201815
NCT02967237Diabetes Mellitus, Type 2 · France4CompletedSanofiJul 24, 2017136
NCT02967224Diabetes Mellitus, Type 2 · Brazil, France, Germany and more4CompletedSanofiOct 16, 2017705
NCT02967211Diabetes Mellitus, Type 2 · Brazil, Finland, France and more4CompletedSanofiOct 20, 2017609
NCT02955953Healthy · Singapore1CompletedEli LillyJan 4, 2017127
NCT02855684Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan3CompletedSanofiAug 6, 2018604
NCT02836704Diabetes Mellitus, Type 2 · China4CompletedSanofiApr 26, 2018892
NCT02787551Diabetes Mellitus, Type 2 · United States, Canada, Estonia and more3CompletedSanofiMay 25, 2018514
NCT02752828Diabetes Mellitus, Type 2 · Japan3CompletedSanofiMar 12, 2018521
NCT02752412Diabetes Mellitus, Type 2 · Japan3CompletedSanofiOct 4, 2018513
NCT02749890Diabetes Mellitus, Type 2 · Japan3CompletedSanofiMay 2018321
NCT02738151Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more4CompletedSanofiAug 15, 2017929
NCT02735044Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3CompletedSanofiMay 31, 2018463
NCT02713477Diabetes Mellitus, Type 2 · Japan1CompletedSanofiJun 201620
NCT02688933Diabetes Mellitus, Type 1 · United States, Puerto Rico4CompletedSanofiJun 19, 2017638
NCT02606357Diabetes Mellitus, Type 2 · Jordan4CompletedSanofiNov 27, 2017242
NCT02545842Diabetes Mellitus, Type 2 · China4CompletedSanofiApr 20, 2018947
NCT02451137Diabetes Mellitus, Type 2 · United States, Canada4CompletedSanofiMar 2, 20183,304
NCT02401243Diabetes Mellitus, Type 2 · Canada3CompletedSanofiFeb 2016253
NCT02320721Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedSanofiMay 20161,014
NCT02302716Diabetes Mellitus, Type 2 · United States, India, Korea, Republic of and more3CompletedEli LillyJul 2016493
NCT02227212Diabetes Mellitus, Type 2 · Germany3CompletedSanofiNov 201440
NCT02201199Diabetes Mellitus, Type 1 · Germany1CompletedSanofiNov 201436
NCT02132637Diabetes Mellitus, Type 2 · United States, Germany3CompletedEli LillyJul 201568
NCT02058160Diabetes Mellitus, Type 2 · United States, Australia, Canada and more3CompletedSanofiJul 2015736
NCT02058147Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more3CompletedSanofiJun 20151,170
NCT02034513Diabetes Mellitus · United States, Poland, Puerto Rico3CompletedNovo NordiskJan 11, 2016501
NCT02030600Diabetes Mellitus · United States, Puerto Rico3CompletedNovo NordiskDec 4, 2015721
NCT02027753Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedSanofiApr 2015109
NCT01868529Diabetes Mellitus · Germany1CompletedNovo NordiskJun 200863
NCT01849289Diabetes Mellitus · United States, Brazil, Canada and more3CompletedNovo NordiskMay 15, 2014833
NCT01838083Type1 Diabetes · Germany1CompletedSanofiAug 201350
NCT01730014Diabetes Mellitus · Germany1CompletedNovo NordiskJul 201370
NCT01704417Diabetes Mellitus · Germany1CompletedNovo NordiskMar 201340
NCT01688635Healthy · Singapore1CompletedEli LillyFeb 201391
NCT01689142Diabetes Mellitus, Type 2 · Japan3CompletedSanofiNov 2013240
NCT01689129Diabetes Mellitus, Type 1 · Japan3CompletedSanofiOct 2013243

How it is read

Names in the registry

  • “insulin glargine”, 38 entries
  • “Insulin Glargine”, 27 entries
  • “Insulin glargine”, 20 entries
  • “INSULIN GLARGINE”, 15 entries
  • “LY2963016”, 11 entries

Codes read as this program: HOE901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.